Publications by authors named "Robert Lupinacci"

Claim this Profile
C
Corrigendum to "A Phase III, multicenter, randomized, double-blind, active comparator-controlled study to evaluate the safety, tolerability, and immunogenicity of V114 compared with PCV13 in healthy infants (PNEU-PED-EU-1)" [Vaccine 41 (2023) 3387-3398].
Federico Martinon-Torres, Jacek Wysocki, Leszek Szenborn, Alfonso Carmona-Martinez, Airi Poder, Robert Lupinacci

Vaccine· February 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A phase 3, single-arm, open-label study to evaluate the safety, tolerability, and immunogenicity of a 15-valent pneumococcal conjugate vaccine, V114, in a 3+1 regimen in healthy infants in South Korea (PNEU-PED-KOR).
Alvino Maestri, Su Eun Park, Fiona Fernandes, Zhongyi Lucy Li, Yae-Jean Kim, Robert Lupinacci

Hum Vaccin Immunother· December 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Effects of PDE10A inhibitor MK-8189 in people with an acute episode of schizophrenia: A randomized proof-of-concept clinical trial.
Yuki Mukai, Robert Lupinacci, Stephen Marder, Linda Snow-Adami, Tiffini Voss

Schizophr Res· August 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
PCV15, a pneumococcal conjugate vaccine, for the prevention of invasive pneumococcal disease in infants and children.
Timothy J Chapman, Liset Olarte, Ghassan Dbaibo, Avril Melissa Houston, Gretchen Tamms, Robert Lupinacci

Expert Rev Vaccines· December 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Safety and Immunogenicity of V114 in Preterm Infants: A Pooled Analysis of Four Phase Three Studies.
Timothy J Chapman, Shrita M Patel, Sheryl A Flores, Shengjie Xu, Robert Lupinacci

Pediatr Infect Dis J· November 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A phase 3 study of safety and immunogenicity of V114, a 15-valent pneumococcal conjugate vaccine, followed by 23-valent pneumococcal polysaccharide vaccine, in children with HIV.
Marissa Wilck, Shaun Barnabas, Kulkanya Chokephaibulkit, Avy Violari, Pope Kosalaraksa, Robert Lupinacci

AIDS· July 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Safety and Tolerability of V114 Pneumococcal Vaccine in Infants: A Phase 3 Study.
Natalie Banniettis, Michael Horn, Manish Sadarangani, Shrita M Patel, David Greenberg, Robert Lupinacci

Pediatrics· July 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A Phase III, multicenter, randomized, double-blind, active comparator-controlled study to evaluate the safety, tolerability, and immunogenicity of V114 compared with PCV13 in healthy infants (PNEU-PED-EU-1).
Federico Martinon-Torres, Jacek Wysocki, Leszek Szenborn, Alfonso Carmona-Martinez, Airi Poder, Robert Lupinacci

Vaccine· May 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Safety, tolerability, and immunogenicity of V114 pneumococcal vaccine compared with PCV13 in a 2+1 regimen in healthy infants: A phase III study (PNEU-PED-EU-2).
Thomas Benfield, Mika Rämet, Piero Valentini, Ilkka Seppä, Ron Dagan, Robert Lupinacci

Vaccine· April 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Safety and immunogenicity of V114, a 15-valent pneumococcal conjugate vaccine, in children with SCD: a V114-023 (PNEU-SICKLE) study.
Charles T Quinn, Richard T Wiedmann, Daniel Jarovsky, Eduardo Lopez-Medina, Hilze M Rodriguez, Robert Lupinacci

Blood Adv· February 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A phase 3, multicenter, randomized, double-blind study to evaluate the interchangeability of V114, a 15-valent pneumococcal conjugate vaccine, and PCV13 with respect to safety, tolerability, and immunogenicity in healthy infants (PNEU-DIRECTION).
Androniki Bili, Scott Dobson, Jeffrey Quinones, Wanatpreeya Phongsamart, Peninnah Oberdorfer, Robert Lupinacci

Vaccine· January 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A phase 3, multicenter, randomized, double-blind, active-comparator-controlled study to evaluate the safety, tolerability, and immunogenicity of a 4-dose regimen of V114, a 15-valent pneumococcal conjugate vaccine, in healthy infants (PNEU-PED).
Robert Lupinacci, Richard Rupp, Orasri Wittawatmongkol, Jake Jones, Jeffrey Quinones

Vaccine· January 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A phase III, multicenter, randomized, double-blind, active comparator-controlled study to evaluate the safety, tolerability, and immunogenicity of catch-up vaccination regimens of V114, a 15-valent pneumococcal conjugate vaccine, in healthy infants, children, and adolescents (PNEU-PLAN).
Natalie Banniettis, Jacek Wysocki, Leszek Szenborn, Wanatpreeya Phongsamart, Punnee Pitisuttithum, Robert Lupinacci

Vaccine· October 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Prognostic and predictive value of AJCC-8 staging in the phase III EORTC1325/KEYNOTE-054 trial of pembrolizumab vs placebo in resected high-risk stage III melanoma.
Alexander M M Eggermont, Christian U Blank, Mario Mandala, Georgina V Long, Victoria G Atkinson, Robert Lupinacci

Eur J Cancer· July 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Sugammadex efficacy for reversal of rocuronium- and vecuronium-induced neuromuscular blockade: A pooled analysis of 26 studies.
William Joseph Herring, Tiffany Woo, Christopher A Assaid, Robert J Lupinacci, Hendrikus J Lemmens

J Clin Anesth· September 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Randomized clinical trial of the efficacy and safety of preservative-free tafluprost and timolol in patients with open-angle glaucoma or ocular hypertension.
Almira Chabi, Rohit Varma, James C Tsai, Robert Lupinacci, Joseph Pigeon

Am J Ophthalmol· June 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Overview of safety experience with caspofungin in clinical trials conducted over the first 15 years: a brief report.
Angela L Ngai, Michael R Bourque, Robert J Lupinacci, Kim M Strohmaier, Nicholas A Kartsonis

Int J Antimicrob Agents· December 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy and safety of caspofungin in obese patients.
Desmond M Ryan, Robert J Lupinacci, Nicholas A Kartsonis

Med Mycol· October 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Caspofungin use in patients with invasive candidiasis caused by common non-albicans Candida species: review of the caspofungin database.
Arnaldo L Colombo, Angela L Ngai, Michael Bourque, Susan K Bradshaw, Kim M Strohmaier, Robert J Lupinacci

Antimicrob Agents Chemother· May 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Invasive candidiasis treated in the intensive care unit: observations from a randomized clinical trial.
Mark J DiNubile, Robert J Lupinacci, Kim M Strohmaier, Carole A Sable, Nicholas A Kartsonis

J Crit Care· September 2007

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pharmacoeconomic analysis of caspofungin versus liposomal amphotericin B as empirical antifungal therapy for neutropenic fever.
John R Wingard, Helen L Leather, Craig A Wood, William C Gerth, Robert J Lupinacci

Am J Health Syst Pharm· March 2007

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy of caspofungin against invasive Candida or invasive Aspergillus infections in neutropenic patients.
Robert Betts, Axel Glasmacher, Johan Maertens, Georg Maschmeyer, Jose A Vazquez, Robert Lupinacci

Cancer· January 2006

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Caspofungin versus liposomal amphotericin B for empirical antifungal therapy in patients with persistent fever and neutropenia.
Thomas J Walsh, Hedy Teppler, Gerald R Donowitz, Johan A Maertens, Lindsey R Baden, Robert J Lupinacci

N Engl J Med· September 2004

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Comparison of caspofungin and amphotericin B for invasive candidiasis.
Jorge Mora-Duarte, Robert Betts, Coleman Rotstein, Arnaldo Lopes Colombo, Luis Thompson-Moya, Robert Lupinacci

N Engl J Med· December 2002

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A randomized double-blind study of caspofungin versus fluconazole for the treatment of esophageal candidiasis.
Alvaro Villanueva, Eduardo Gotuzzo, Eduardo G Arathoon, L Miguel Noriega, Nicholas A Kartsonis, Robert J Lupinacci

Am J Med· September 2002

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis